Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AFMD Affimed NV

0.026 (5.78%)
Dec 04 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 378,318
Bid Price 0.4544
Ask Price 0.476
News (1)
Day High 0.4737


52 Week Range


Day Low 0.44
Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.026 5.78% 0.476 19:57:19
Open Price Low Price High Price Close Price Prev Close
0.4737 0.44 0.4737 0.4544 0.45
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,215 378,318 $ 0.4550769 $ 172,164 - 0.2235 - 2.15
Last Trade Time Type Quantity Stock Price Currency
19:35:12 3 $ 0.4759 USD

Affimed NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
68.7M 149.34M - 42.77M -86M -0.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Affimed NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No AFMD Message Board. Create One! See More Posts on AFMD Message Board See More Message Board Posts

Historical AFMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.47150.550.4110.4855483648,1460.00450.95%
1 Month0.3640.550.31060.422095737,0260.11230.77%
3 Months0.530.550.22350.4270893628,441-0.054-10.19%
6 Months0.8780.8780.22350.5506248788,029-0.402-45.79%
1 Year2.082.150.22350.89710061,016,191-1.60-77.12%
3 Years5.2511.740.22354.831,492,670-4.77-90.93%
5 Years4.5511.740.22354.381,240,208-4.07-89.54%

Affimed NV Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Your Recent History

Delayed Upgrade Clock